Literature DB >> 23147758

Diagnosis and treatment of lupus nephritis flares--an update.

Ben Sprangers1, Marianne Monahan, Gerald B Appel.   

Abstract

Relapses or flares of systemic lupus erythematosus (SLE) are frequent and observed in 27-66% of patients. SLE flares are defined as an increase in disease activity, in general, requiring alternative treatment or intensification of therapy. A renal flare is indicated by an increase in proteinuria and/or serum creatinine concentration, abnormal urine sediment or a reduction in creatinine clearance rate as a result of active disease. The morbidity associated with renal flares is derived from both the kidney damage due to lupus nephritis and treatment-related toxic effects. Current induction treatment protocols achieve remission in the majority of patients with lupus nephritis; however, few studies focus on treatment interventions for renal flares in these patients. The available data, however, suggest that remission can be induced again in a substantial percentage of patients experiencing a lupus nephritis flare. Lupus nephritis flares are independently associated with an increased risk of deterioration in renal function; prevention of renal flares might, therefore, also decrease long-term morbidity and mortality. Appropriate immunosuppressive maintenance therapy might lead to a decrease in the occurrence of renal and extrarenal flares in patients with SLE, and monitoring for the early detection and treatment of renal flares could improve their outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23147758     DOI: 10.1038/nrneph.2012.220

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  83 in total

1.  Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.

Authors:  Frédéric A Houssiau; Carlos Vasconcelos; David D'Cruz; Gian Domenico Sebastiani; Enrique de Ramon Garrido; Maria Giovanna Danieli; Daniel Abramovicz; Daniel Blockmans; Alessandro Mathieu; Haner Direskeneli; Mauro Galeazzi; Ahmet Gül; Yair Levy; Peter Petera; Rajko Popovic; Radmila Petrovic; Renato Alberto Sinico; Roberto Cattaneo; Josep Font; Geneviève Depresseux; Jean-Pierre Cosyns; Ricard Cervera
Journal:  Arthritis Rheum       Date:  2004-12

2.  Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.

Authors:  Tak-Mao Chan; Kai-Chung Tse; Colin Siu-On Tang; Mo-Yin Mok; Fu-Keung Li
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

3.  Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide.

Authors:  E Ciruelo; J de la Cruz; I López; J J Gómez-Reino
Journal:  Arthritis Rheum       Date:  1996-12

4.  Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis.

Authors:  Tamar Rubinstein; Milena Pitashny; Benjamin Levine; Noa Schwartz; Julie Schwartzman; Elena Weinstein; Jose M Pego-Reigosa; Tim Y-T Lu; David Isenberg; Anisur Rahman; Chaim Putterman
Journal:  Rheumatology (Oxford)       Date:  2010-02-09       Impact factor: 7.580

5.  Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Authors:  Mary Anne Dooley; David Jayne; Ellen M Ginzler; David Isenberg; Nancy J Olsen; David Wofsy; Frank Eitner; Gerald B Appel; Gabriel Contreras; Laura Lisk; Neil Solomons
Journal:  N Engl J Med       Date:  2011-11-17       Impact factor: 91.245

6.  Urine chemokines as biomarkers of human systemic lupus erythematosus activity.

Authors:  Brad H Rovin; Huijuan Song; Dan J Birmingham; Lee A Hebert; Chack Yung Yu; Haikady N Nagaraja
Journal:  J Am Soc Nephrol       Date:  2004-12-15       Impact factor: 10.121

7.  Prediction of urinary protein markers in lupus nephritis.

Authors:  Jim C Oates; Sanju Varghese; Alison M Bland; Timothy P Taylor; Sally E Self; Romesh Stanislaus; Jonas S Almeida; John M Arthur
Journal:  Kidney Int       Date:  2005-12       Impact factor: 10.612

8.  Clinical and prognostic value of serial renal biopsies in lupus nephritis.

Authors:  G Moroni; S Pasquali; S Quaglini; G Banfi; S Casanova; M Maccario; P Zucchelli; C Ponticelli
Journal:  Am J Kidney Dis       Date:  1999-09       Impact factor: 8.860

Review 9.  Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature.

Authors:  Marlene T Anderka; Angela E Lin; Dianne N Abuelo; Allen A Mitchell; Sonja A Rasmussen
Journal:  Am J Med Genet A       Date:  2009-06       Impact factor: 2.802

10.  Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Authors:  Frédéric A Houssiau; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Radmila Petrovic; Christoph Fiehn; Enrique de Ramon Garrido; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2010-09-10       Impact factor: 19.103

View more
  31 in total

1.  [Lupus nephritis].

Authors:  S Melderis; T Wiech; C Iking-Konert; O M Steinmetz
Journal:  Z Rheumatol       Date:  2018-09       Impact factor: 1.372

2.  Identification of stage-specific genes associated with lupus nephritis and response to remission induction in (NZB × NZW)F1 and NZM2410 mice.

Authors:  Ramalingam Bethunaickan; Celine C Berthier; Weijia Zhang; Ridvan Eksi; Hong-Dong Li; Yuanfang Guan; Matthias Kretzler; Anne Davidson
Journal:  Arthritis Rheumatol       Date:  2014-08       Impact factor: 10.995

3.  Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis.

Authors:  Julie E Davidson; Qinggong Fu; Beulah Ji; Sapna Rao; David Roth; Laurence S Magder; Michelle Petri
Journal:  J Rheumatol       Date:  2018-03-01       Impact factor: 4.666

4.  Diagnostic value of progranulin in patients with lupus nephritis and its correlation with disease activity.

Authors:  Jiabin Wu; Lixin Wei; Weiming Wang; Xianghui Zhang; Li Chen; Changda Lin
Journal:  Rheumatol Int       Date:  2016-03-11       Impact factor: 2.631

Review 5.  CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis - from bench to bedside?

Authors:  L Schiffer; K Worthmann; H Haller; M Schiffer
Journal:  Clin Exp Immunol       Date:  2015-01       Impact factor: 4.330

6.  Clinical analysis of multi-target treatment for complex lupus nephritis.

Authors:  Feng Ye; Shanzhi Wang; Min Wang; Huanan Wang; Feng Guo; Guoquan Li; Nan Liu
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

7.  Omics-based integrated analysis identified IKZF2 as a biomarker associated with lupus nephritis.

Authors:  Mi Zhou; Yuening Kang; Jun Li; Rongxiu Li; Liangjing Lu
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

8.  Exacerbating lupus nephritis following BPA exposure is associated with abnormal autophagy in MRL/lpr mice.

Authors:  Youdan Dong; Zeming Zhang; Hezuo Liu; Lihong Jia; Muting Qin; Xiaofei Wang
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

9.  Colony-stimulating factor-1: a potential biomarker for lupus nephritis.

Authors:  Julia Menke; Kerstin Amann; Lorenzo Cavagna; Maria Blettner; Arndt Weinmann; Andreas Schwarting; Vicki R Kelley
Journal:  J Am Soc Nephrol       Date:  2014-07-10       Impact factor: 10.121

10.  Pathogenetic role of glomerular CXCL13 expression in lupus nephritis.

Authors:  K Worthmann; F Gueler; S von Vietinghoff; A Davalos-Mißlitz; F Wiehler; A Davidson; T Witte; H Haller; M Schiffer; C S Falk; L Schiffer
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.